[Federal Register Volume 67, Number 15 (Wednesday, January 23, 2002)]
[Notices]
[Page 3168]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-1645]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Concerning Indolo[2,1-b]quinazole-6, 12-dione 
Antimalarial Compounds and Methods of Treating Malaria

AGENCY: U.S. Army Medical Research and Materiel Command, DOD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the 
availability for licensing of U.S. Patent No. 6,284,772 entitled 
``Indolo[2,1-b]quinazole-6, 12-dione antimalarial compounds and Methods 
of Treating Malaria'' issued 09/04/01. Foreign rights are also 
available (PCT/US99/22569). This patent has been assigned to the United 
States Government as represented by the Secretary of the Army.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, Maryland 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664. Both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: Compounds, compositions and methods are 
provided for treating malaria parasites in vitro and in vivo by 
administering indolo [2,1-b]quinazoline-6, 12-dione compounds of 
Formula 1. On Formula 1 A, B, C, D, E, F, G and H are independently 
selected from carbon and nitrogen, or A and B or C and D can be taken 
together to be nitrogen or sulfer, with the proviso that not more than 
three of A, B, C, D, E, F, G and H are other than carbon; wherein R1 
through R8 are independently selected from the group consisting of, but 
not limited to, the halogens, alkyl groups, trifluoromethyl groups, 
methoxyl groups, the carboxy methyl or carboxy ethyl group, nitro, 
aryl, heteroaryl, cyano, amino, dialkylaminoalkyl, 1-(4-
alkylpiperazinyl), and the pharmaceutically acceptable salts thereof; 
and wherein X is independently selected from the group consisting of 
any atom especially oxygen, or any side chain necessary to make the 
indolo[2,1-b]quinazoline-6, 12-dione compound a ``prodrug'' as the term 
is understood by one of ordinary skill in the art of medicinal 
chemistry. In other words, a side chain having a structure where a 
carbon-nitrogen double bond bears substituents that make the prodrug 
more water soluble and bioavailable.

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-1645 Filed 1-22-02; 8:45 am]
BILLING CODE 3710-08-M